Neuropathix

We are thrilled to announce that Kannalife has received $1.49 million in funding from The Michael J. Fox Foundation for Parkinson's Research! This generous grant will support the development of our lead therapeutic, KLS-13019, which addresses neuroinflammation and mitochondrial dysfunction in Parkinson's disease. A great big thank you to our team and partners for their dedication and hard work. Together, we are making strides towards better treatments and improving lives. Neuropathix

Kannalife Secures Funding of $1.49 Million from The Michael J. Fox Foundation for Parkinson’s Research Funding of $1.49 million USD to support the development of KLS-13019 targeting neuroinflammation and mitochondrial dysfunction Kannalife has...

Please join Neuropathix on October 11, 2023 at the NIH Life Sciences Summit at the Alexandria Life Sciences Center in NYC to see our subsidiary Kannalife Sciences, take center stage!

We're proud to be only one of fifteen innovative, fundable, early-stage life sciences companies selected by NIH to present our breakthrough technology to treat neuropathic pain, inflammation and addiction.

https://lifesciencessummit.org/presenters-23/

Emerging Company Showcase – Life Sciences Summit Innovative, Fundable, Early Stage Opportunities Each company featured in the 2023 Emerging Company Showcase was nominated, reviewed and invited to present based upon their innovative science and the quality of their management team. They presented before a panel of ‘Pitch Doctors’, early stage V...

Neuropathix Highlights Revenue Related to its Grant Award with NIH-NINDS

Neuropathix, Inc. Highlights Revenue Related to its Grant Award with NIH-NINDS 97 million Phase 2 STTR Study Grant through the NIH HEAL Initiative (Helping End Addiction Long-term) is providing funding specifically in the Development of KLS-13019 for Neuropathic PainDOYLESTOWN, PA / ACCESSWIRE / May 25, 2022 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a....